Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 3, 2005
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer
M M Mita, L Ochoa, E K Rowinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
E K Rowinsky, R Humphrey, L A Hammond, et al.
British Journal of Cancer
|
April 3, 2003
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
A W Tolcher, S L Gerson, L Denis, et al.
British Journal of Cancer
|
July 22, 2004
An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium
R G Keedwell, Y Zhao, L A Hammond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies
L A Hammond, J R Eckardt, S D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2000
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer
A Patnaik, E K Rowinsky, B K Tammara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 1998
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide
L A Hammond, J R Eckardt, R Ganapathi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo, L L Siu, J Nemunaitis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2004
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity
J S de Bono, S Y Rha, J Stephenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 30, 2000
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies
E K Rowinsky, T R Johnson, C E Geyer, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 3, 2005
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer
M M Mita, L Ochoa, E K Rowinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
E K Rowinsky, R Humphrey, L A Hammond, et al.
British Journal of Cancer
|
April 3, 2003
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
A W Tolcher, S L Gerson, L Denis, et al.
British Journal of Cancer
|
July 22, 2004
An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium
R G Keedwell, Y Zhao, L A Hammond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies
L A Hammond, J R Eckardt, S D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2000
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer
A Patnaik, E K Rowinsky, B K Tammara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 1998
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide
L A Hammond, J R Eckardt, R Ganapathi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo, L L Siu, J Nemunaitis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2004
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity
J S de Bono, S Y Rha, J Stephenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 30, 2000
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies
E K Rowinsky, T R Johnson, C E Geyer, et al.
Page
of 3